This technology describes the development of immunogenic compounds to serve as ligands for natural killer T cells to modulate immune responses.
Natural killer T cells are T lymphocytes that play a critical role in cytokine production and are involved in controlling cancer, infection and are essential for several aspects of immunity. CD1 molecules are a family of highly conserved antigen presenting proteins that display a variety of lipids and glycolipids to T cells. A great diversity of lipids and glycolipids have been shown to bind to the various isoforms of CD1 and activate natural killer T cells. Modulating the activity of these cells could be a way to enhance the immune response of an organism.
This technology describes a series of novel compounds that have been identified to act as ligands for natural killer T cells and modulate the immune response of these cells. They are useful for developing vaccines for treating a variety of diseases and disorders that require immunotherapy and stimulation of natural killer T cells.
IR CU22361
Licensing Contact: Kristin Neuman